65,437 trials
Vitiligo · Melanoma (Skin) · Nonmelanoma Skin Cancer
Primary: Number of New Onset Skin Cancer in Adult People Diagnosed With Vitiligo — 133; 812 Participants
Breast Feeding, Exclusive
Primary: Exclusive Breastfeeding (EBF) — 9; 4; 11; 13 Participants
Peripheral Artery Disease
Primary: Six-minute Walk Distance (NR Alone vs. Placebo) — -6.93; 7.00; -10.58 meters — p=0.0775
Bipolar Disorder
Primary: Change in BMI Z-score From Baseline to Month 6 in ITT Sample — -0.08; 0.00 Z-score — p=<0.001
Clinical Deterioration · Hospital Medicine · Monitoring, Physiologic
Primary: Overall Rate of Escalation — 12.3; 11.3 escalations per 1,000 patient bed days — p=< 0.001
Hearing Loss
Primary: Spectral Resolution — 3.5; 3.3; 3.2; 2.8 units on a scale — p=.774
Healthy
Primary: Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) — 1; 0; 0; 3 Participants
Drink Too Much · Drinking, Binge · Drunk
Primary: Number of Safety Actions Taken to Intervene Within Group — 2.14; 1.90 score on a scale — p=<0.001
Cancer
Primary: Statement of Treatment Preferences (SOTP) a Tool to Measure Goals of Care. — 10; 22; 38; 19 Dyads — p=<0.05
Metastatic or Unresectable Melanoma
Primary: Best Overall Response as Defined by RECIST 1.1 Criteria — 0 Participants
Healthy
Primary: Number of Participants With One or More Treatment-Emergent Adverse Event(s) (TEAEs) — 4; 8; 8; 7 Participants
Opioid-use Disorder · Opioid-Related Disorders
Primary: In-hospital Initiation of MOUD Therapy — 94; 43 Participants
Axial Spondyloarthritis · Crohn Disease
Primary: The Sensitivity and Specificity of MRE as a Screening Tool for Axial Spondyloarthritis in Crohn's Disease — 0.88; 0.50; 0.78 Probability
Malignant Melanoma
Primary: PFS Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (by Blinded Independent Central Review (BICR) — 35; 34 Participants — p=0.845
Metastatic Cancer
Primary: Overall Survival — 42.0; 43.5 percentage of participants